Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Subject must have completed or be an eligible Baseline failure from the parent study (SP0982 \[NCT02408523\]). Note: Other subjects screened for SP0982 may be considered for roll-over to EP0012 if the investigator considers that the subject could benefit from treatment with open-label lacosamide (LCM) and based on prior discussion with and approval from the UCB Study Physician or representative~Exclusion Criteria:~* Subject is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM)~* Subject meets the withdrawal criteria for SP0982 or is experiencing an ongoing serious adverse event (SAE)~* Subject has an active suicidal ideation as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Since Last Visit version of the Columbia-Suicide Severity Rating Scale (C-SSRS)~* Subject has \>=2x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are \>ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35%). For all subjects who entered EP0012 directly with a Baseline result \>ULN for ALT, AST, ALP, or total bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the electronic Case Report form (eCRF). Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Start dose~SP0982 completers at V1:~* LCM 10 mg/kg/day for pediatric subjects weighing \<30 kg~* LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to \<50 kg~* LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~SP0982 Baseline failures at V1:~* LCM 2 mg/kg/day for pediatric subjects weighing \<50 kg~* LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~Oral solution (pediatric subjects \<50 kg):~* Minimum LCM dose: 4 mg/kg/day~* Maximum LCM dose: 12 mg/kg/day~Tablets (pediatric subjects ≥50kg):~* Minimum LCM dose: 200 mg/day~* Minimum LCM dose: 600 mg/day~Tablets (adult subjects):~* Minimum LCM dose: 200 mg/day~* Maximum LCM dose: 800 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).